| 词条 | Karin Briner |
| 释义 |
Karin Briner is a medicinal chemist and pharmaceutical executive currently employed as the Vice President and Global Head of Chemistry at Novartis. {{Infobox scientist| name = Karin Briner, Ph.D. | nationality = Swiss | doctoral_advisor = Andrea Vasella | academic_advisors = William Roush }} EducationBriner received her B.S. and Ph.D. degrees working at the University of Zurich with Professor Andrea Vasella.[1] She pursued postdoctoral studies at Indiana University with Prof. William Roush,[2] developing new methods to stereoselectively synthesize natural product glycosides.[3] CareerAfter completing postdoctoral studies, Briner was hired at Eli Lilly & Company as a Senior Chemist in Infectious Diseases. Her work eventually evolved into central nervous system disorders such as depression, evidenced by multiple selective compounds against various serotonin receptors. She became the Managing Director of the Lilly Research Centre, UK, from 2007-2010. Briner was hired by the Novartis Institutes for Biomedical Research as the Global Head of Chemistry in 2011. Since that time, her team has been involved in the development of multiple new drug launches, for example nilotinib,[4] ceritinib, panobinostat, and Entresto. Volunteer serviceBriner was a founding member of the Innovative Medicines Initiative (IMI), and remains active in professional societies such as the European Federation for Medicinal Chemistry[5] and the American Chemical Society. She has delivered plenary talks at multiple scientific meetings.[6] She remains active in a mentoring capacity to incoming postdoctoral and Summer scholars at Novartis.[7] Briner maintains an entry for the chemical production and purification of elemental lithium at EROS.[8] References1. ^{{Cite web|url=https://www.novartis.com/our-science/postdoc-program/leadership/karin-briner-phd|title=Karin Briner, Ph.D. {{!}} Novartis|website=Novartis|access-date=2018-10-22}} {{DEFAULTSORT:Briner, Karin}}2. ^{{Cite web|url=https://www.scripps.edu/roush/People.html|title=Roush Research Personnel|website=www.scripps.edu|access-date=2018-10-22}} 3. ^{{Cite journal|last=Roush|first=William R.|last2=Briner|first2=Karin|last3=Kesler|first3=Brenda S.|last4=Murphy|first4=Megan|last5=Gustin|first5=Darin J.|date=January 1996|title=Studies on the Synthesis of Aureolic Acid Antibiotics: Acyloin Glycosidation Studies|journal=The Journal of Organic Chemistry|volume=61|issue=18|pages=6098–6099|doi=10.1021/jo960932e|pmid=11667440|issn=0022-3263}} 4. ^{{Cite web|url=https://cen.acs.org/articles/90/i41/MerckCo-Novartis-Arkema-Chemists-Honored.html|title=Merck & Co., Novartis, And Arkema Chemists Honored For Discoveries {{!}} Chemical & Engineering News|last=Ainsworth|first=Susan J.|website=cen.acs.org|access-date=2018-10-22}} 5. ^{{Cite web|url=https://www.efmc.info/content.php?langue=english&cle_menus=1201086347|title=EFMC Scientific Advisory Board|website=www.efmc.info|access-date=2018-10-22}} 6. ^{{Cite web|url=https://tpa.acs.org/session/248tNM/MEDI/evolution-of-medicinal-chemistry-outlook-and-opportunities|title=Evolution of Medicinal Chemistry: Outlook and Opportunities|last=Briner|first=Karin|date=2014|website=|archive-url=|archive-date=|dead-url=|access-date=October 2018}} 7. ^{{Cite web|url=https://www.novartis.com/our-science/postdoc-program/leadership/karin-briner-phd|title=Karin Briner, Ph.D. {{!}} Novartis|website=Novartis|access-date=2018-10-22}} 8. ^{{Citation|last=Briner|first=Karin|title=Lithium|date=2014-10-20|work=Encyclopedia of Reagents for Organic Synthesis|pages=1–8|publisher=John Wiley & Sons, Ltd|doi=10.1002/047084289x.rl034.pub3|isbn=9780470842898|last2=Mathes|first2=Brian M.|last3=Ramón|first3=Diego J.|last4=Yus|first4=Miguel}} 4 : Swiss biochemists|Living people|Swiss business executives|Year of birth missing (living people) |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。